Author’s response to reviews

Title: Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer

Authors:

Timothy O'Donnell (timodonnell@gmail.com)

Elizabeth Christie (Elizabeth.Christie@petermac.org)

Arun Ahuja (aahuja11@gmail.com)

Jacqueline Buros (jcki@hammerlab.org)

Bulent Arman Aksoy (arman@hammerlab.org)

David Bowtell (david.bowtell@petermac.org)

Alexandra Snyder Charen (snyderca@mskcc.org)

Jeffrey Hammerbacher (jeff@hammerlab.org)

Version: 2 Date: 2017-11-21

Author’s response to reviews:

Nov. 21, 2017

Dear Dr. Strong,

Thank you for considering our manuscript "Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer" (BCAN-D-16-02613). We appreciate the effort that went into reviewing our manuscript and are pleased to hear that it is potentially acceptable for publication in BMC Cancer.

We have revised the manuscript as suggested by the Editor, detailed below.

Thank you for the time you have invested in our manuscript. Please don’t hesitate to let us know if you see other opportunities to improve it.
Sincerely,

Alexandra Snyder
Memorial Sloan Kettering Cancer Center

Jeff Hammerbacher
Icahn School of Medicine at Mount Sinai

Editor Comments:

1. Please include the full names of the ethics committees (and the institute to which it belongs to) that approved the study and the committees' reference number if appropriate in the "Ethics approval and consent to participate" section.

This section has been revised to read:

As described in ref. [Patch et al Nature 2015], the Australian Ovarian Cancer Study was approved by the Human Research Ethics Committees at the Peter MacCallum Cancer Centre, Queensland Institute of Medical Research, University of Melbourne and all participating hospitals. Written informed consent was obtained from all participants in this study.

2. In the section 'Funding', please also describe the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

A second sentence has been added to this section, which now reads:
This research was supported by the Parker Institute for Cancer Immunotherapy, the Marsha Rivkin Foundation, and NIH/NCI Cancer Center Support Grant P30 CA008748. Funding organizations were not involved in the design of the study, the collection, analysis, and interpretation of data and in writing the manuscript.

3. Please add a statement to your “Authors’ contributions” confirming that all authors read and approved the final manuscript.

Added: “All authors read, revised, and approved the final manuscript.”

4. Please provide email addresses for all the co-authors on the title page.

We have added a title page with this information.

5. Please ensure that all figures/tables and supplementary files are cited within the text. Any items which are not cited may be deleted by our production department upon publication.

Done.

6. Please remove the response to reviewers comments file as this is not needed at this stage.

Done.
7. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Done.